The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

NCT05774275 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

High-Risk Localized Soft Tissue Sarcoma

Interventions

DRUG: Pegylated Liposomal Doxorubicin
DRUG: Doxorubicin
DRUG: Anti-PD-1 monoclonal antibody
RADIATION: Radiotherapy

Sponsor

Fudan University